Complete remission of psoriasis following bevacizumab therapy for colon cancer

Authors: Akman, A.; Yilmaz, E.; Mutlu, H.; Ozdogan, M.

Source: Clinical & Experimental Dermatology, Volume 34, Number 5, July 2009 , pp. e202-e204(3)

Buy & download fulltext article:

Price: $48.00 plus tax (Refund Policy)

Abstract:

Summary

Bevacizumab is a monoclonal antibody against vascular endothelial growth factor (VEGF), which is used to treat several cancers. Currently, experience with anti-VEGF treatment for psoriasis is limited, and no published reports on this use exist. We describe a patient with metastatic colon cancer and psoriasis who experienced complete remission of psoriasis during treatment with bevacizumab and combination chemotherapy without any other treatment for psoriasis. These data suggest that bevacizumab may be a promising therapeutic agent for the treatment of psoriasis.

Document Type: Research article

DOI: http://dx.doi.org/10.1111/j.1365-2230.2008.02991.x

Affiliations: 1: Medical Oncology, School of Medicine Antalya, Antalya, Turkey

Publication date: 2009-07-01